OverviewSuggest Edit

Apricus Biosciences is a biopharmaceutical company which focuses on the development and commercialization of product candidates in the areas of urology and rheumatology. Its lead product is Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction. The Company also engages in developing other medicines to treat rheumatoid and urological disease.

... Show more
TypePublic
Founded1987
HQSan Diego, US
Websiteapricusbio.com
Employee Ratings3.2

Latest Updates

Employees (est.) (Sep 2017)15
Revenue (FY, 2016)$5.8 M(+20%)
Share Price (Jan 2019)$0.2 (-2%)

Key People/Management at Apricus Biosciences

Richard Pascoe

Richard Pascoe

CEO
Brian Dorsey

Brian Dorsey

Senior Vice President, Chief Development Officer
Neil Morton

Neil Morton

Senior Vice President, Chief Business Officer
Mary Naggs

Mary Naggs

Vice President, General Counsel
Kelly Deck

Kelly Deck

Executive Director, Finance
Show more

Apricus Biosciences Office Locations

Apricus Biosciences has an office in San Diego
San Diego, US (HQ)
11975 El Camino Real, Ste 300
Show all (1)
Report incorrect company information

Apricus Biosciences Financials and Metrics

Apricus Biosciences Revenue

Apricus Biosciences's revenue was reported to be $5.76 m in FY, 2016 which is a 19.1% increase from the previous period.
USD

Net income (Q2, 2018)

(2.3m)

Market capitalization (23-Jan-2019)

6.2m

Closing stock price (23-Jan-2019)

0.2

Cash (30-Jun-2018)

6.8m
Apricus Biosciences's current market capitalization is $6.2 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

2.5m9.3m4.8m5.8m

Revenue growth, %

269%(48%)19%

Cost of goods sold

23.0k918.0k922.0k511.0k

Gross profit

2.5m8.3m3.9m5.3m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

28.0k5.5m1.9m475.0k462.0k1.3m626.0k464.0k4.3m

Cost of goods sold

75.0k485.0k233.0k509.0k142.0k233.0k93.0k111.0k

Gross profit

5.4m1.4m242.0k(47.0k)1.1m393.0k371.0k4.2m

Gross profit Margin, %

99%74%51%(10%)89%63%80%97%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

21.4m11.4m3.9m2.1m6.3m

Accounts Receivable

59.0k678.0k519.0k530.0k

Inventories

336.0k275.0k469.0k764.0k

Current Assets

22.3m13.3m6.3m3.6m6.6m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

20.6m22.5m17.4m16.1m16.2m7.4m5.8m6.9m2.7m5.6m3.8m7.8m8.5m5.7m6.8m

Accounts Receivable

35.0k69.0k49.0k829.0k513.0k664.0k575.0k688.0k687.0k398.0k

Inventories

338.0k364.0k377.0k321.0k217.0k411.0k142.0k405.0k778.0k800.0k

Current Assets

21.7m23.5m18.8m18.4m18.0m9.8m8.2m9.1m4.9m7.2m5.1m8.6m8.7m5.9m7.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(16.9m)(21.8m)(19.0m)(7.4m)321.0k

Depreciation and Amortization

77.0k170.0k300.0k289.0k117.0k

Inventories

(341.0k)61.0k(194.0k)(295.0k)

Accounts Payable

(920.0k)(66.0k)609.0k(509.0k)(705.0k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(15.6m)(3.3m)(1.4m)(4.5m)(6.4m)(5.0m)(2.5m)(5.8m)(7.1m)8.1m(2.3m)wdxefcqufszuzezftuxetqsqxt(4.5m)

Depreciation and Amortization

57.0k20.0k40.0k102.0k149.0k73.0k145.0k217.0k13.0k23.0k

Inventories

(338.0k)(28.0k)(41.0k)15.0k217.0k(136.0k)142.0k64.0k(73.0k)(140.0k)

Accounts Payable

(1.5m)67.0k202.0k295.0k880.0k(442.0k)417.0k(374.0k)133.0k(225.0k)485.0k286.0k996.0k
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information

Apricus Biosciences Online and Social Media Presence

Embed Graph
Report incorrect company information

Apricus Biosciences News and Updates

Seelos Therapeutics, Inc. Announces Successful Completion of its Merger with Apricus Biosciences, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders

NEW YORK, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders, …

Apricus Biosciences Stockholders Approve Proposed Merger with Seelos Therapeutics, Inc.

Merger Expected to Close in January 2019 Merger Expected to Close in January 2019

Raynauds Disease Treatment Market is touching new level – A comprehensive study with key players Allergan Plc, Apricus Biosciences, Bayer AG

HTF MI released a new market study on Global Raynauds Disease Treatment Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assess…

Apricus Biosciences Adjourns Special Meeting of Stockholders to New Date

The Meeting Seeking Stockholder Approval for Proposed Merger with Seelos Therapeutics, Inc. Will Be Reconvened on January 4, 2019 The Meeting Seeking Stockholder Approval for Proposed Merger with Seelos Therapeutics, Inc. Will Be Reconvened on January 4, 2019

Apricus Biosciences Provides Corporate Update and Third Quarter 2018 Financial Results

Company Merger with Seelos Therapeutics, Inc. Expected to Close in Fourth Quarter 2018

Apricus Biosciences, Inc. Announces Merger Agreement with Seelos Therapeutics, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders

NEW YORK, July 30, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI) announced the signing of a definitive agreement to merge with Seelos Therapeutics, Inc., a privately-held biotechnology company, in an all-stock transaction. The merged company will focus on the development and co…
Report incorrect company information

Apricus Biosciences Company Life and Culture

Report incorrect company information

Apricus Biosciences Frequently Asked Questions

  • When was Apricus Biosciences founded?

    Apricus Biosciences was founded in 1987.

  • Who are Apricus Biosciences key executives?

    Apricus Biosciences's key executives are Richard Pascoe, Brian Dorsey and Neil Morton.

  • How many employees does Apricus Biosciences have?

    Apricus Biosciences has 15 employees.

  • Who are Apricus Biosciences competitors?

    Competitors of Apricus Biosciences include Biogen, MyoKardia and Athersys.

  • Where is Apricus Biosciences headquarters?

    Apricus Biosciences headquarters is located at 11975 El Camino Real, Ste 300 , San Diego.

  • Where are Apricus Biosciences offices?

    Apricus Biosciences has an office in San Diego.

  • How many offices does Apricus Biosciences have?

    Apricus Biosciences has 1 office.